{"entity":{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","aka":[],"tldr":"MaaT Pharma makes gut microbiome treatments for people with blood cancer. Its lead product restores gut bacteria to treat a severe complication of stem cell transplants when standard drugs fail.","summary":"MaaT Pharma (Euronext Paris: MAAT), founded in 2014 in Lyon, develops Microbiome Ecosystem Therapies supported by its gutPrint AI discovery engine and in-house cGMP manufacturing. Lead product Xervyteg (MaaT013), a pooled full-ecosystem microbiome therapy, is intended for steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation; more than 230 patients have been treated under early access across 13 countries. In June 2026 the EMA's CHMP issued a negative opinion and MaaT Pharma said it would request re-examination. MaaT033, an oral capsule, is in the PHOEBUS trial in allogeneic transplant recipients, described as potentially pivotal in Europe, with one-year overall survival data expected in late 2028. Cash was EUR 18.1 million at 31 March 2026; a EUR 6 million European Investment Bank loan tranche drawn in April 2026 extended runway to November 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.maatpharma.com"},{"label":"Q1 2026 business update","url":"https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/"},{"label":"Plan to request re-examination after negative CHMP opinion (June 2026)","url":"https://www.maatpharma.com/june-26-2026-maat-pharma-announces-plan-to-request-re-examination-following-negative-chmp-opinion-for-maat013-for-the-treatment-of-acute-graft-versus-host-disease/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.maatpharma.com","ticker":"MAAT.PA","founded":2014,"stage":"public","investors":[],"funding":[{"round":"Debt","year":2026,"source":"https://www.maatpharma.com/may-26-2026-maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026/","note":"Tranche B of EUR 6 million drawn from a European Investment Bank loan facility in April 2026"}]},"route":"/companies/maat-pharma/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"trial":[{"id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","route":"/trials/nct07001618/"}],"roadmap":[{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/"}]}}